As provider reimbursement begins to move toward models that favor quality over quantity, CEO compensation may be following the same path-with CEO pay determined more by quality measures than strictly by financial gains.
As provider reimbursement begins to move toward models that favor quality over quantity, CEO compensation may be following the same path—with CEO pay determined more by quality measures than strictly by financial gains. By focusing on quality measures, hospitals can show that they are committed to improving patient outcomes and wellness. Some health systems are even finding that the benefits of transitioning to quality-based measures far outweigh the challenges.
“In an environment where there will be a bonus or an incentive for performance, I don't think it’s reasonable to have it based purely on financial performance,” said Ana Pujols-McKee, MD, executive vice president and chief medical officer of the Joint Commission. “Quality is the product we’re paying for as the consumers. That’s what we expect.”
Ascension Health, a not-for-profit health system, found that quality measures in annual incentive plans increased executives’ salaries by 10% to 80%, and 40% to 100% in 3-year incentive plans.
Still, for those hospitals that treat disproportionate numbers of sickly and poor, the gains are less even. An expert research panel found that while Medicare and private insurers pay for quality of care, they do not account for factors such as a patients’ education or income.
“Factors far outside the control of a doctor or hospital—patients’ income, housing, education, even race—can significantly affect patient health, healthcare, and providers’ performance scores,” said Christine K. Cassel, MD, president and CEO, National Quality Forum.
Low-income individuals often cannot afford certain medications, and even when they can, those with low levels of literacy might not understand the written instructions they’ve received from their physician. Although some clinical factors such as diabetes are taken into consideration, hospitals feel as though they are being treated unfairly when they are penalized for missing quality benchmarks which result from treating large numbers of poor and sickly patients.
“The administration’s current policy on adjustments for socioeconomic status are quite inadvertently exacerbating disparities in access to medical care for poor people who live in isolated neighborhoods. I’m sure that’s not what President Obama intended with the Affordable Care Act,” said Steven H. Lipstein, president, BJC HealthCare in St Louis, Missouri, and expert on the research panel. “Readmissions are difficult to avoid in patients who can’t afford post-discharge medications, have no social support to help with recovery at home, have no way to get to follow-up doctor appointments, or are homeless.”
Future quality-based reimbursement models may center on comparing hospitals with “peer groups,” or providers who treat similar patient populations.
Around the Web
Bonuses Still Tied to Better Financials [Modern Healthcare]
Health Law’s Pay Policy Is Skewed, Panel Finds [The New York Times]
New Blueprint Guides Patient-Centered Research for More Equitable Health Care
July 17th 2025The new Blueprint for Patient-Centered Value Research offers a roadmap for embedding patient voices throughout every stage of the research journey to foster more equitable, transparent, and responsive health care systems.
Read More
Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs
June 10th 2025Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Listen
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Driving Value via Outcomes-Based Pricing and EHR Interoperability: Tyler Sandahl, PharmD
July 7th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, discussed the complexities of alternative payment models for chimeric antigen receptor T-cell and bispecific therapies and the need for improved data sharing in cancer care.
Read More
Moving Evidence From Research to Practice: Q&A With Ken Cohen, MD
June 23rd 2025In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with Ken Cohen, MD, executive director of translational research at Optum Health.
Read More